Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million

Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million

FinvizFinviz2026/02/12 21:06
By:Finviz

BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offering of 16,644,737 shares of its common stock, including the full exercise of the underwriters’ option to purchase up to 2,171,052 additional shares, at a public offering price of $19.00 per share. The aggregate gross proceeds to Galecto from the offering were approximately $316.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Galecto.

Jefferies, Leerink Partners, Evercore ISI and Guggenheim Securities acted as joint book-running managers for the offering.

An automatically effective shelf registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) on February 10, 2026. This offering was made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement.

About Galecto, Inc.

Galecto, Inc. is a clinical-stage biotechnology company advancing a pipeline of antibody therapeutics to transform treatment of a broad spectrum of hematological cancers. Galecto’s pipeline includes a highly differentiated mutant calreticulin (mut-CALR)-driven myeloproliferative neoplasm portfolio targeting essential thrombocythemia and myelofibrosis. Galecto’s pipeline also includes GB3226, a first-in-class preclinical dual inhibitor of ENL-YEATS and FLT3 for the treatment of multiple genetic subsets of acute myeloid leukemia.


0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

White House Pressure Fails to Prevent Hawkish Shift! Federal Reserve Rate Hike Looms, Waller-Trump Relationship Faces Major Test

The Federal Reserve is expected to raise interest rates by 25 basis points on Wednesday, marking the first increase since 2023; the market is pricing in a probability of over 90%, and the relationship between the White House and Walsh faces a test.

智通财经2026/09/16 01:06
White House Pressure Fails to Prevent Hawkish Shift! Federal Reserve Rate Hike Looms, Waller-Trump Relationship Faces Major Test